Gerd Pluschke

List of Publications by Year
in descending order

138 papers	3,910 citations	101543 36 h-index	175258 52 g-index
145 all docs	145 docs citations	145 times ranked	2864 citing authors

#	Article	IF	Citations
1	Overview: Mycobacterium ulcerans Disease (Buruli Ulcer). Methods in Molecular Biology, 2022, 2387, 3-6.	0.9	0
2	Investigation of Mycobacterium ulcerans Glycan Interactions Using Glycan and Surface Plasmon. Methods in Molecular Biology, 2022, 2387, 29-40.	0.9	1
3	Overview: Mycolactone, the Macrolide Toxin of Mycobacterium ulcerans. Methods in Molecular Biology, 2022, 2387, 105-108.	0.9	1
4	Overview: Development of Drugs Against Mycobacterium ulcerans. Methods in Molecular Biology, 2022, 2387, 185-187.	0.9	2
5	Aberrant stromal tissue factor localisation and mycolactone-driven vascular dysfunction, exacerbated by IL-1Î², are linked to fibrin formation in Buruli ulcer lesions. PLoS Pathogens, 2022, 18, e1010280.	4.7	5
6	Scalable Process for High-Yield Production of PfCyRPA Using Insect Cells for Inclusion in a Malaria Virosome-Based Vaccine Candidate. Frontiers in Bioengineering and Biotechnology, 2022, 10, .	4.1	6
7	The cell surface protein MUL_3720 confers binding of the skin pathogen Mycobacterium ulcerans to sulfated glycans and keratin. PLoS Neglected Tropical Diseases, 2021, 15, e0009136.	3.0	0
8	An Antigen Capture Assay for the Detection of Mycolactone, the Polyketide Toxin of <i>Mycobacterium ulcerans</i>. Journal of Immunology, 2021, 206, 2753-2762.	0.8	3
9	Inhibition of the SEC61 translocon by mycolactone induces a protective autophagic response controlled by EIF2S1-dependent translation that does not require ULK1 activity. Autophagy, 2021, , 1-19.	9.1	6
10	Nanotechnological immunoassay for rapid label-free analysis of candidate malaria vaccines. Nanoscale, 2021, 13, 2338-2349.	5.6	11
11	Alternative Complement Pathway Inhibition Abrogates Pneumococcal Opsonophagocytosis in Vaccine-NaÃ¯ve, but Not in Vaccinated Individuals. Frontiers in Immunology, 2021, 12, 732146.	4.8	14
12	Alternative Complement Pathway Inhibition Does Not Abrogate Meningococcal Killing by Serum of Vaccinated Individuals. Frontiers in Immunology, 2021, 12, 747594.	4.8	17
13	Efficacy of an acid-oxidising solution (AOS) against Mycobacterium ulcerans. Antimicrobial Agents and Chemotherapy, 2021, , AAC0087021.	3.2	0
14	Chronic wounds in Sierra Leone: Searching for Buruli ulcer, a NTD caused by Mycobacterium ulcerans, at Masanga Hospital. PLoS Neglected Tropical Diseases, 2021, 15, e0009862.	3.0	0
15	Bacterial genome-wide association study of hyper-virulent pneumococcal serotype 1 identifies genetic variation associated with neurotropism. Communications Biology, 2020, 3, 559.	4.4	11
16	Introduction of Mycobacterium ulcerans disease in the Bankim Health District of Cameroon follows damming of the MapÃ© River. PLoS Neglected Tropical Diseases, 2020, 14, e0008501.	3.0	5
17	wIRA: hyperthermia as a treatment option for intracellular bacteria, with special focus on Chlamydiae and Mycobacteria. International Journal of Hyperthermia, 2020, 37, 373-383.	2.5	11
18	Buruli ulcer: The Efficacy of Innate Immune Defense May Be a Key Determinant for the Outcome of Infection With Mycobacterium ulcerans. Frontiers in Microbiology, 2020, 11, 1018.	3.5	12

#	Article	IF	Citations
19	Toward a Single-Dose Cure for Buruli Ulcer. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	16
20	Development of an ELISA for the quantification of mycolactone, the cytotoxic macrolide toxin of Mycobacterium ulcerans. PLoS Neglected Tropical Diseases, 2020, 14, e0008357.	3.0	9
21	Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models. Npj Vaccines, 2020, 5, 9.	6.0	16
22	The immunology of other mycobacteria: M. ulcerans, M. leprae. Seminars in Immunopathology, 2020, 42, 333-353.	6.1	21
23	Configurationally Stabilized Analogs of <i>M. ulcerans</i> Exotoxins Mycolactones A and B Reveal the Importance of Side Chain Geometry for Mycolactone Virulence. Organic Letters, 2019, 21, 5853-5857.	4.6	11
24	Thermal field formation during wIRA-hyperthermia: temperature measurements in skin and subcutis of piglets as a basis for thermotherapy of superficial tumors and local skin infections caused by thermosensitive microbial pathogens. International Journal of Hyperthermia, 2019, 36, 937-951.	2.5	10
25	Mycolactone: More than Just a Cytotoxin. , 2019, , 117-134.		26
26	Buruli Ulcer: History and Disease Burden. , 2019, , 1-41.		12
27	Buruli Ulcer in Africa. , 2019, , 43-60.		6
28	Laboratory Diagnosis of Buruli Ulcer: Challenges and Future Perspectives. , 2019, , 183-202.		11
29	Development of Dengue Virus Serotypeâ€“Specific NS1 Capture Assays for the Rapid and Highly Sensitive Identification of the Infecting Serotype in Human Sera. Journal of Immunology, 2018, 200, 3857-3866.	0.8	11
30	Targeting the Mycobacterium ulcerans cytochrome bc1:aa3 for the treatment of Buruli ulcer. Nature Communications, 2018, 9, 5370.	12.8	64
31	Transmission of Hepatitis B and D Viruses in an African Rural Community. MSystems, 2018, 3, .	3.8	5
32	Loss of Genomic Diversity in a Neisseria meningitidis Clone Through a Colonization Bottleneck. Genome Biology and Evolution, 2018, 10, 2102-2109.	2.5	2
33	Spontaneous point mutations in the capsule synthesis locus leading to structural and functional changes of the capsule in serogroup A meningococcal populations. Virulence, 2018, 9, 1138-1149.	4.4	5
34	Community knowledge, perceptions and attitudes regarding leprosy in rural Cameroon: The case of Ekondotiti and Mbonge health districts in the South-west Region. PLoS Neglected Tropical Diseases, 2018, 12, e0006233.	3.0	21
35	Characteristics and epidemiological profile of Buruli ulcer in the district of TiassalÃ©, south CÃ´te dâ€™Ivoire. Acta Tropica, 2017, 175, 138-144.	2.0	18
36	The global distribution and diversity of protein vaccine candidate antigens in the highly virulent Streptococcus pnuemoniae serotype 1. Vaccine, 2017, 35, 972-980.	3.8	27

#	Article	IF	Citations
37	Exudate collection using wound spongesâ€"An easy, nonâ€invasive and reliable method to explore protease activities in ulcers. Wound Repair and Regeneration, 2017, 25, 320-326.	3.0	10
38	The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chemical Biology, 2017, 12, 1297-1307.	3.4	62
39	Infiltrating leukocytes surround early Buruli ulcer lesions, but are unable to reach the mycolactone producing mycobacteria. Virulence, 2017, 8, 1918-1926.	4.4	31
40	Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibody. ELife, 2017, 6, .	6.0	50
41	Susceptibility to Mycobacterium ulcerans Disease (Buruli ulcer) Is Associated with IFNG and iNOS Gene Polymorphisms. Frontiers in Microbiology, 2017, 8, 1903.	3.5	26
42	Assessing and managing wounds of Buruli ulcer patients at the primary and secondary health care levels in Ghana. PLoS Neglected Tropical Diseases, 2017, 11, e0005331.	3.0	19
43	Genomic analysis of ST88 community-acquired methicillin resistant<i>Staphylococcus aureus</i>in Ghana. PeerJ, 2017, 5, e3047.	2.0	20
44	Vaccination with the Surface Proteins MUL_2232 and MUL_3720 of Mycobacterium ulcerans Induces Antibodies but Fails to Provide Protection against Buruli Ulcer. PLoS Neglected Tropical Diseases, 2016, 10, e0004431.	3.0	23
45	Local Cellular Immune Responses and Pathogenesis of Buruli Ulcer Lesions in the Experimental Mycobacterium Ulcerans Pig Infection Model. PLoS Neglected Tropical Diseases, 2016, 10, e0004678.	3.0	21
46	Spatial Distribution of Mycobacterium ulcerans in Buruli Ulcer Lesions: Implications for Laboratory Diagnosis. PLoS Neglected Tropical Diseases, 2016, 10, e0004767.	3.0	18
47	Spatiotemporal Co-existence of Two Mycobacterium ulcerans Clonal Complexes in the Offin River Valley of Ghana. PLoS Neglected Tropical Diseases, 2016, 10, e0004856.	3.0	7
48	Mycobacterium ulcerans Mouse Model Refinement for Pre-Clinical Profiling of Vaccine Candidates. PLoS ONE, 2016, 11, e0167059.	2.5	12
49	Generation of monoclonal antibodies against native viral proteins using antigen-expressing mammalian cells for mouse immunization. BMC Biotechnology, 2016, 16, 83.	3.3	7
50	Understanding pneumococcal serotype 1 biology through population genomic analysis. BMC Infectious Diseases, 2016, 16, 649.	2.9	22
51	Generation of Plasmodium falciparum parasite-inhibitory antibodies by immunization with recombinantly-expressed CyRPA. Malaria Journal, 2016, 15, 161.	2.3	17
52	Local Heat Application for the Treatment of Buruli Ulcer: Results of a Phase II Open Label Single Center Non Comparative Clinical Trial. Clinical Infectious Diseases, 2016, 62, 342-350.	5.8	27
53	Comparative Study of Activities of a Diverse Set of Antimycobacterial Agents against Mycobacterium tuberculosis and Mycobacterium ulcerans. Antimicrobial Agents and Chemotherapy, 2016, 60, 3132-3137.	3.2	15
54	Buruli Ulcer in Cameroon: The Development and Impact of the National Control Programme. PLoS Neglected Tropical Diseases, 2016, 10, e0004224.	3.0	15

#	Article	IF	Citations
55	Socio-Environmental Factors Associated with the Risk of Contracting Buruli Ulcer in TiassalÃ©, South CÃ´te dâ€™Ivoire: A Case-Control Study. PLoS Neglected Tropical Diseases, 2016, 10, e0004327.	3.0	19
56	A Sero-epidemiological Approach to Explore Transmission of Mycobacterium ulcerans. PLoS Neglected Tropical Diseases, 2016, 10, e0004387.	3.0	14
57	Interferon-Î³ Is a Crucial Activator of Early Host Immune Defense against Mycobacterium ulcerans Infection in Mice. PLoS Neglected Tropical Diseases, 2016, 10, e0004450.	3.0	30
58	Burden and Historical Trend of Buruli Ulcer Prevalence in Selected Communities along the Offin River of Ghana. PLoS Neglected Tropical Diseases, 2016, 10, e0004603.	3.0	18
59	Antibody-Mediated Neutralization of the Exotoxin Mycolactone, the Main Virulence Factor Produced by Mycobacterium ulcerans. PLoS Neglected Tropical Diseases, 2016, 10, e0004808.	3.0	38
60	Limited Genetic Diversity of Hepatitis B Virus in the General Population of the Offin River Valley in Ghana. PLoS ONE, 2016, 11, e0156864.	2.5	10
61	Development of a bead-based Luminex assay using lipopolysaccharide specific monoclonal antibodies to detect biological threats from Brucella species. BMC Microbiology, 2015, 15, 198.	3.3	22
62	A Synthetic Virus-Like Particle Streptococcal Vaccine Candidate Using B-Cell Epitopes from the Proline-Rich Region of Pneumococcal Surface Protein A. Vaccines, 2015, 3, 850-874.	4.4	24
63	Locally Confined Clonal Complexes of Mycobacterium ulcerans in Two Buruli Ulcer Endemic Regions of Cameroon. PLoS Neglected Tropical Diseases, 2015, 9, e0003802.	3.0	26
64	Selamectin Is the Avermectin with the Best Potential for Buruli Ulcer Treatment. PLoS Neglected Tropical Diseases, 2015, 9, e0003996.	3.0	19
65	DNA Methylation Assessed by SMRT Sequencing Is Linked to Mutations in Neisseria meningitidis Isolates. PLoS ONE, 2015, 10, e0144612.	2.5	16
66	Mycolactone-Dependent Depletion of Endothelial Cell Thrombomodulin Is Strongly Associated with Fibrin Deposition in Buruli Ulcer Lesions. PLoS Pathogens, 2015, 11, e1005011.	4.7	38
67	Identification of the Mycobacterium ulcerans Protein MUL_3720 as a Promising Target for the Development of a Diagnostic Test for Buruli Ulcer. PLoS Neglected Tropical Diseases, 2015, 9, e0003477.	3.0	24
68	Mycobacterium ulcerans Disease (Buruli Ulcer): Potential Reservoirs and Vectors. Current Clinical Microbiology Reports, 2015, 2, 35-43.	3.4	25
69	Challenges Associated with Management of Buruli Ulcer/Human Immunodeficiency Virus Coinfection in a Treatment Center in Ghana: A Case Series Study. American Journal of Tropical Medicine and Hygiene, 2015, 93, 216-223.	1.4	13
70	Region-specific diversification of the highly virulent serotype 1 Streptococcus pneumoniae. Microbial Genomics, 2015, 1, e000027.	2.0	27
71	Use of Recombinant Virus Replicon Particles for Vaccination against Mycobacterium ulcerans Disease. PLoS Neglected Tropical Diseases, 2015, 9, e0004011.	3.0	19
72	Complete Healing of a Laboratory-Confirmed Buruli Ulcer Lesion after Receiving Only Herbal Household Remedies. PLoS Neglected Tropical Diseases, 2015, 9, e0004102.	3.0	4

#	Article	IF	Citations
73	Mycobacterium ulcerans Disease. , 2014, , 519-531.e2.		17
74	Primary cultivation: factors affecting contamination and Mycobacterium ulcerans growth after long turnover time of clinical specimens. BMC Infectious Diseases, 2014, 14, 636.	2.9	18
75	Mycobacterium ulcerans Persistence at a Village Water Source of Buruli Ulcer Patients. PLoS Neglected Tropical Diseases, 2014, 8, e2756.	3.0	43
76	Immunohistochemical Monitoring of Wound Healing in Antibiotic Treated Buruli Ulcer Patients. PLoS Neglected Tropical Diseases, 2014, 8, e2809.	3.0	14
77	Late Onset of the Serological Response against the 18 kDa Small Heat Shock Protein of Mycobacterium ulcerans in Children. PLoS Neglected Tropical Diseases, 2014, 8, e2904.	3.0	31
78	Experimental Infection of the Pig with Mycobacterium ulcerans: A Novel Model for Studying the Pathogenesis of Buruli Ulcer Disease. PLoS Neglected Tropical Diseases, 2014, 8, e2968.	3.0	22
79	Emergence of a New Epidemic Neisseria meningitidis Serogroup A Clone in the African Meningitis Belt: High-Resolution Picture of Genomic Changes That Mediate Immune Evasion. MBio, 2014, 5, e01974-14.	4.1	51
80	Global Phylogenomic Analysis of Nonencapsulated<i>Streptococcus pneumoniae</i>Reveals a Deep-Branching Classic Lineage That Is Distinct from Multiple Sporadic Lineages. Genome Biology and Evolution, 2014, 6, 3281-3294.	2.5	63
81	A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on Generalized Modules for Membrane Antigens (GMMA). Vaccine, 2014, 32, 2688-2695.	3.8	55
82	Characterization of vaccine antigens of meningococcal serogroup W isolates from Ghana and Burkina Faso from 2003 to 2009. F1000Research, 2014, 3, 264.	1.6	6
83	Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. Vaccine, 2013, 31, 1453-1457.	3.8	35
84	Lack of antigenic diversification of major outer membrane proteins during clonal waves ofNeisseria meningitidisserogroup A colonization and disease. Pathogens and Disease, 2013, 67, 4-10.	2.0	7
85	Secondary Bacterial Infections of Buruli Ulcer Lesions Before and After Chemotherapy with Streptomycin and Rifampicin. PLoS Neglected Tropical Diseases, 2013, 7, e2191.	3.0	48
86	Structure-Activity Relationship Studies on the Macrolide Exotoxin Mycolactone of Mycobacterium ulcerans. PLoS Neglected Tropical Diseases, 2013, 7, e2143.	3.0	53
87	Geographic Distribution, Age Pattern and Sites of Lesions in a Cohort of Buruli Ulcer Patients from the MapÃ© Basin of Cameroon. PLoS Neglected Tropical Diseases, 2013, 7, e2252.	3.0	73
88	A Case of Cutaneous Tuberculosis in a Buruli Ulcerâ€"Endemic Area. PLoS Neglected Tropical Diseases, 2012, 6, e1751.	3.0	9
89	Development of a Temperature-Switch PCR-Based SNP Typing Method for Mycobacterium ulcerans. PLoS Neglected Tropical Diseases, 2012, 6, e1904.	3.0	5
90	Sero-Epidemiology as a Tool to Screen Populations for Exposure to Mycobacterium ulcerans. PLoS Neglected Tropical Diseases, 2012, 6, e1460.	3.0	34

#	Article	IF	Citations
91	Passive Immunoprotection of <i>Plasmodium falciparum</i>-Infected Mice Designates the CyRPA as Candidate Malaria Vaccine Antigen. Journal of Immunology, 2012, 188, 6225-6237.	0.8	60
92	Screening of Antifungal Azole Drugs and Agrochemicals with an Adapted alamarBlue-Based Assay Demonstrates Antibacterial Activity of Croconazole against Mycobacterium ulcerans. Antimicrobial Agents and Chemotherapy, 2012, 56, 6410-6413.	3.2	13
93	Chemotherapy-Associated Changes of Histopathological Features of Mycobacterium ulcerans Lesions in a Buruli Ulcer Mouse Model. Antimicrobial Agents and Chemotherapy, 2012, 56, 687-696.	3.2	23
94	Development of a virosomal malaria vaccine candidate: from synthetic peptide design to clinical concept validation. Future Virology, 2012, 7, 779-790.	1.8	4
95	On the origin of Mycobacterium ulcerans, the causative agent of Buruli ulcer. BMC Genomics, 2012, 13, 258.	2.8	139
96	The genome, evolution and diversity of Mycobacterium ulcerans. Infection, Genetics and Evolution, 2012, 12, 522-529.	2.3	54
97	A Ringâ€Closing Metathesis (RCM)â€Based Approach to Mycolactonesâ€…A/B. Chemistry - A European Journal, 2011, 17, 13017-13031.	3.3	45
98	Oral Treatment for Mycobacterium ulcerans Infection: Results From a Pilot Study in Benin. Clinical Infectious Diseases, 2011, 52, 94-96.	5.8	109
99	Combining PCR with Microscopy to Reduce Costs of Laboratory Diagnosis of Buruli Ulcer. American Journal of Tropical Medicine and Hygiene, 2011, 85, 900-904.	1.4	28
100	Histopathological Changes and Clinical Responses of Buruli Ulcer Plaque Lesions during Chemotherapy: A Role for Surgical Removal of Necrotic Tissue?. PLoS Neglected Tropical Diseases, 2011, 5, e1334.	3.0	33
101	Secondary Buruli Ulcer Skin Lesions Emerging Several Months after Completion of Chemotherapy: Paradoxical Reaction or Evidence for Immune Protection?. PLoS Neglected Tropical Diseases, 2011, 5, e1252.	3.0	62
102	Virosome-Formulated Plasmodium falciparum AMA-1 & CSP Derived Peptides as Malaria Vaccine: Randomized Phase 1b Trial in Semi-Immune Adults & Children. PLoS ONE, 2011, 6, e22273.	2.5	61
103	Virosomal technology in malaria vaccine development. Future Virology, 2010, 5, 247-250.	1.8	2
104	Synthetic glycosylphosphatidylinositol microarray reveals differential antibody levels and fine specificities in children with mild and severe malaria. Bioorganic and Medicinal Chemistry, 2010, 18, 3747-3752.	3.0	17
105	An efficient system to generate monoclonal antibodies against membrane-associated proteins by immunisation with antigen-expressing mammalian cells. BMC Biotechnology, 2010, 10, 87.	3.3	26
106	Single Nucleotide Polymorphism Typing of Mycobacterium ulcerans Reveals Focal Transmission of Buruli Ulcer in a Highly Endemic Region of Ghana. PLoS Neglected Tropical Diseases, 2010, 4, e751.	3.0	51
107	Optimized DNA Preparation from Mycobacteria. Cold Spring Harbor Protocols, 2010, 2010, pdb.prot5408.	0.3	21
108	Immunosuppression and treatment-associated inflammatory response in patients withMycobacterium ulceransinfection (Buruli ulcer). Expert Opinion on Biological Therapy, 2009, 9, 187-200.	3.1	39

#	Article	IF	Citations
109	Genomic Diversity and Evolution of Mycobacterium ulcerans Revealed by Next-Generation Sequencing. PLoS Pathogens, 2009, 5, e1000580.	4.7	68
110	Buruli ulcer disease: prospects for a vaccine. Medical Microbiology and Immunology, 2009, 198, 69-77.	4.8	42
111	Design and pre-clinical profiling of a Plasmodium falciparum MSP-3 derived component for a multi-valent virosomal malaria vaccine. Malaria Journal, 2009, 8, 314.	2.3	8
112	Phase Change Material for Thermotherapy of Buruli Ulcer: A Prospective Observational Single Centre Proof-of-Principle Trial. PLoS Neglected Tropical Diseases, 2009, 3, e380.	3.0	48
113	Independent Loss of Immunogenic Proteins in <i>Mycobacterium ulcerans</i> Suggests Immune Evasion. Vaccine Journal, 2008, 15, 598-606.	3.1	33
114	Improved Protective Efficacy of a Species-Specific DNA Vaccine Encoding Mycolyl-Transferase Ag85A from Mycobacterium ulcerans by Homologous Protein Boosting. PLoS Neglected Tropical Diseases, 2008, 2, e199.	3.0	48
115	Clonal Waves of Neisseria Colonisation and Disease in the African Meningitis Belt: Eight- Year Longitudinal Study in Northern Ghana. PLoS Medicine, 2007, 4, e101.	8.4	81
116	Genetic diversification of Neisseria meningitidis during waves of colonization and disease in the meningitis belt of sub-Saharan Africa. Vaccine, 2007, 25, A18-A23.	3.8	11
117	Development of Highly Organized Lymphoid Structures in Buruli Ulcer Lesions after Treatment with Rifampicin and Streptomycin. PLoS Neglected Tropical Diseases, 2007, 1, e2.	3.0	58
118	A Randomized Placebo-Controlled Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Synthetic Peptides in Healthy Adult Volunteers. PLoS ONE, 2007, 2, e1018.	2.5	53
119	A Virosomal Malaria Peptide Vaccine Elicits a Long-Lasting Sporozoite-Inhibitory Antibody Response in a Phase 1a Clinical Trial. PLoS ONE, 2007, 2, e1278.	2.5	49
120	Structure-Activity-Based Design of a Synthetic Malaria Peptide Eliciting Sporozoite Inhibitory Antibodies in a Virosomal Formulation. Chemistry and Biology, 2007, 14, 577-587.	6.0	34
121	Local Activation of the Innate Immune System in Buruli Ulcer Lesions. Journal of Investigative Dermatology, 2007, 127, 638-645.	0.7	27
122	Evolution of two distinct phylogenetic lineages of the emerging human pathogen Mycobacterium ulcerans. BMC Evolutionary Biology, 2007, 7, 177.	3.2	81
123	Contiguous spread ofMycobacterium ulcerans in Buruli ulcer lesions analysed by histopathology and real-time PCR quantification of mycobacterial DNA. Journal of Pathology, 2006, 208, 119-128.	4.5	52
124	Synthesis, Solution Structure and Immune Recognition of an Epidermal Growth Factor-Like Domain from Plasmodium falciparum Merozoite Surface Protein-1. ChemBioChem, 2006, 7, 1943-1950.	2.6	14
125	Use of the Immunodominant 18-Kilodalton Small Heat Shock Protein as a Serological Marker for Exposure to Mycobacterium ulcerans. Vaccine Journal, 2006, 13, 1314-1321.	3.1	57
126	Buruli Ulcer (M. ulcerans Infection): New Insights, New Hope for Disease Control. PLoS Medicine, 2005, 2, e108.	8.4	205

#	Article	IF	Citations
127	Evaluation of Decontamination Methods and Growth Media for Primary Isolation of Mycobacterium ulcerans from Surgical Specimens. Journal of Clinical Microbiology, 2004, 42, 5875-5876.	3.9	52
128	Cyclic Peptidomimetics Derived from the Apical Membrane Antigen I ofPlasmodium falciparum and Their Use in Malaria Vaccine Design. Helvetica Chimica Acta, 2003, 86, 3638-3647.	1.6	0
129	Title is missing!. Angewandte Chemie, 2003, 115, 2470-2473.	2.0	2
130	A Virosome-Mimotope Approach to Synthetic Vaccine Design and Optimization: Synthesis, Conformation, and Immune Recognition of a Potential Malaria-Vaccine Candidate. Angewandte Chemie - International Edition, 2003, 42, 2368-2371.	13.8	37
131	The Nâ€™-Terminal Domain of Glyceraldehyde-3-Phosphate Dehydrogenase of the Apicomplexan Plasmodium falciparum Mediates GTPase Rab2-Dependent Recruitment to Membranes. Biological Chemistry, 2003, 384, 1227-37.	2.5	66
132	Induction of Parasite Growth-Inhibitory Antibodies by a Virosomal Formulation of a Peptidomimetic of Loop I from Domain III of Plasmodium falciparum Apical Membrane Antigen 1. Infection and Immunity, 2003, 71, 4749-4758.	2.2	91
133	Exploiting Conformationally Constrained Peptidomimetics and an Efficient Human-Compatible Delivery System in Synthetic Vaccine Design. ChemBioChem, 2002, 3, 270-270.	2.6	1
134	Exploiting Conformationally Constrained Peptidomimetics and an Efficient Human-Compatible Delivery System in Synthetic Vaccine Design. ChemBioChem, 2001, 2, 838.	2.6	52
135	Rhoptry-Associated Protein 1-Binding Monoclonal Antibody Raised against a Heterologous Peptide Sequence Inhibits Plasmodium falciparum Growth In Vitro. Infection and Immunity, 2001, 69, 2558-2568.	2.2	20
136	Microheterogeneity of serogroup A (subgroup III) Neisseria meningitidis during an outbreak in northern Ghana. Tropical Medicine and International Health, 2000, 5, 280-287.	2.3	30
137	Generation of chimeric monoclonal antibodies from mice that carry human immunoglobulin CÎ³1 heavy or CÎº light chain gene segments. Journal of Immunological Methods, 1998, 215, 27-37.	1.4	15
138	Epidemiology and disease burden of Buruli ulcer: a review. Research and Reports in Tropical Medicine, 0, , 59.	1.4	17